White Paper

Lowering The Lipids Barrier: The Key To Accelerating RNA-LNP Drug Development


The remarkable success of LNP-based mRNA technology in combating SARS-CoV-2 has made it one of the most exciting fields in medicine right now. mRNA's potential to enable highly rapid and scalable drug development is a key reason why it is considered such a significant breakthrough. Since precise tuning is required for lipid nanoparticle compositions to deliver payload efficiently, developers need solutions that simplify and streamline the complex, lengthy processes involved in lipid candidate selection and LNP composition optimization.

In this white paper, you will learn about the drug development hurdles that must be overcome to deliver on the promise of mRNA. The challenge of selecting and optimizing a successful ionizable lipid mix in the early development stages is the primary focus, and the paper explores the amount of time required when starting from scratch in this process. Further, it examines the benefits of off-the-shelf ionizable lipids and reagent kits that have been pre-developed and pre-optimized for a diverse range of genomic medicine applications. Finally, the white paper seeks to quantify how much faster a new nanomedicine-based drug candidate could be brought to the clinic with access to the portfolio of ionizable lipids and reagent kits developed by Precision NanoSystems.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Cell & Gene